|PhaseRx Inc -- USA Stock|| |
USD 0.28 0.0194 6.47%
Dr. Allan S. Hoffman, Ph.D., is CoFounder of PhaseRx, Inc. He is also a Professor of Bioengineering, University of Washington. He studied at Massachusetts Institute of Technology, where he received BS, MS, and ScD degrees in Chemical Engineering between 1953 and 1957. He taught on the faculty of the Chemical Engineering Department at M.I.T. for a total of ten years, and for the past 40 years he was Professor of Bioengineering and Chemical Engineering at the University of Washington in Seattle, Washington, United States of America.
The company has return on total asset (ROA)
of (64.2) %
which means that it has lost $64.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (228.17) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 5.44 M in liabilities with Debt to Equity (D/E) ratio of 264.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PhaseRx Inc has Current Ratio of 2.1 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. On December 11, 2017, PhaseRx, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. PhaseRx operates under Biotechnology classification in USA and traded on BATS Exchange exchange. It employs 10 people.PhaseRx Inc (PZRX) is traded on BATS Exchange in USA. It is located in WASHINGTON, U.S.A and employs 10 people. PhaseRx is listed under Pharmaceutical Products category by Fama And French industry classification.